Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer

Simon B. Zeichner, Tulay Sengul, Nikesh Shah, Qingyun Liu, Nathan J. Markward, Alberto J. Montero, Stefan Glück, Orlando Silva, Eugene R. Ahn

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background Vitamin D (VD) supplementation has pleiotropic effects that extend beyond their impact on bone health, including the disruption of downstream VD receptor signaling and human epidermal growth factor receptor 2 (HER2) signaling through the ErbB2/AKT/ERK pathway. In the present study, we examined our institutional experience with patients having nonmetastatic HER2-positive (HER+) breast cancer and hypothesized that those patients who received VD supplementation during neoadjuvant chemotherapy would have improved long-term outcomes.

Patients and Methods We performed a retrospective review of all patients (n = 308) given trastuzumab-based chemotherapy between 2006 and 2012 at the University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC). We identified 2 groups of patients for comparison - those who received VD supplementation during neoadjuvant chemotherapy (n = 134) and those who did not (n = 112). Univariate and multivariate Cox proportional hazard regression models were fitted to overall survival (OS) and disease-free survival (DFS).

Results More than half of the patients received VD during neoadjuvant chemotherapy (54.5%), with 60% receiving a dose < 10,000 units/wk and 33.3% having a VD deficiency at the start of therapy. In our final multivariate model, VD use was associated with improved DFS (hazard ratio [HR], 0.36; 95% confidence interval [CI], 0.15-0.88; P =.026], whereas larger tumor size was associated with worse DFS (HR, 3.52; 95% CI, 1.06-11.66; P =.04). There were no differences in OS based on any of the categories, including VD use, tumor size, number of metastatic lymph nodes, age at diagnosis, or lymphovascular invasion (LVI).

Conclusion VD supplementation in patients with nonmetastatic HER2+ breast cancer is associated with improved DFS.

Original languageEnglish
Pages (from-to)e1-e11
JournalClinical Breast Cancer
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Adjuvant Chemotherapy
Vitamin D
Breast Neoplasms
Disease-Free Survival
Drug Therapy
Confidence Intervals
Neoplasms
Calcitriol Receptors
Vitamin D Deficiency
Survival
MAP Kinase Signaling System
human ERBB2 protein
Proportional Hazards Models
Lymph Nodes
Bone and Bones
Health

Keywords

  • Calcitriol
  • ErbB2/AKT/ERK pathway
  • Pleiotropic effects
  • Trastuzumab
  • Vitamin D receptor
  • Vitamin D supplementation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. / Zeichner, Simon B.; Sengul, Tulay; Shah, Nikesh; Liu, Qingyun; Markward, Nathan J.; Montero, Alberto J.; Glück, Stefan; Silva, Orlando; Ahn, Eugene R.

In: Clinical Breast Cancer, Vol. 15, No. 1, 01.01.2015, p. e1-e11.

Research output: Contribution to journalArticle

Zeichner, Simon B. ; Sengul, Tulay ; Shah, Nikesh ; Liu, Qingyun ; Markward, Nathan J. ; Montero, Alberto J. ; Glück, Stefan ; Silva, Orlando ; Ahn, Eugene R. / Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. In: Clinical Breast Cancer. 2015 ; Vol. 15, No. 1. pp. e1-e11.
@article{fdff58e8b0ed438b92055148f9d98112,
title = "Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer",
abstract = "Background Vitamin D (VD) supplementation has pleiotropic effects that extend beyond their impact on bone health, including the disruption of downstream VD receptor signaling and human epidermal growth factor receptor 2 (HER2) signaling through the ErbB2/AKT/ERK pathway. In the present study, we examined our institutional experience with patients having nonmetastatic HER2-positive (HER+) breast cancer and hypothesized that those patients who received VD supplementation during neoadjuvant chemotherapy would have improved long-term outcomes.Patients and Methods We performed a retrospective review of all patients (n = 308) given trastuzumab-based chemotherapy between 2006 and 2012 at the University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC). We identified 2 groups of patients for comparison - those who received VD supplementation during neoadjuvant chemotherapy (n = 134) and those who did not (n = 112). Univariate and multivariate Cox proportional hazard regression models were fitted to overall survival (OS) and disease-free survival (DFS).Results More than half of the patients received VD during neoadjuvant chemotherapy (54.5{\%}), with 60{\%} receiving a dose < 10,000 units/wk and 33.3{\%} having a VD deficiency at the start of therapy. In our final multivariate model, VD use was associated with improved DFS (hazard ratio [HR], 0.36; 95{\%} confidence interval [CI], 0.15-0.88; P =.026], whereas larger tumor size was associated with worse DFS (HR, 3.52; 95{\%} CI, 1.06-11.66; P =.04). There were no differences in OS based on any of the categories, including VD use, tumor size, number of metastatic lymph nodes, age at diagnosis, or lymphovascular invasion (LVI).Conclusion VD supplementation in patients with nonmetastatic HER2+ breast cancer is associated with improved DFS.",
keywords = "Calcitriol, ErbB2/AKT/ERK pathway, Pleiotropic effects, Trastuzumab, Vitamin D receptor, Vitamin D supplementation",
author = "Zeichner, {Simon B.} and Tulay Sengul and Nikesh Shah and Qingyun Liu and Markward, {Nathan J.} and Montero, {Alberto J.} and Stefan Gl{\"u}ck and Orlando Silva and Ahn, {Eugene R.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2014.08.001",
language = "English",
volume = "15",
pages = "e1--e11",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer

AU - Zeichner, Simon B.

AU - Sengul, Tulay

AU - Shah, Nikesh

AU - Liu, Qingyun

AU - Markward, Nathan J.

AU - Montero, Alberto J.

AU - Glück, Stefan

AU - Silva, Orlando

AU - Ahn, Eugene R.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background Vitamin D (VD) supplementation has pleiotropic effects that extend beyond their impact on bone health, including the disruption of downstream VD receptor signaling and human epidermal growth factor receptor 2 (HER2) signaling through the ErbB2/AKT/ERK pathway. In the present study, we examined our institutional experience with patients having nonmetastatic HER2-positive (HER+) breast cancer and hypothesized that those patients who received VD supplementation during neoadjuvant chemotherapy would have improved long-term outcomes.Patients and Methods We performed a retrospective review of all patients (n = 308) given trastuzumab-based chemotherapy between 2006 and 2012 at the University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC). We identified 2 groups of patients for comparison - those who received VD supplementation during neoadjuvant chemotherapy (n = 134) and those who did not (n = 112). Univariate and multivariate Cox proportional hazard regression models were fitted to overall survival (OS) and disease-free survival (DFS).Results More than half of the patients received VD during neoadjuvant chemotherapy (54.5%), with 60% receiving a dose < 10,000 units/wk and 33.3% having a VD deficiency at the start of therapy. In our final multivariate model, VD use was associated with improved DFS (hazard ratio [HR], 0.36; 95% confidence interval [CI], 0.15-0.88; P =.026], whereas larger tumor size was associated with worse DFS (HR, 3.52; 95% CI, 1.06-11.66; P =.04). There were no differences in OS based on any of the categories, including VD use, tumor size, number of metastatic lymph nodes, age at diagnosis, or lymphovascular invasion (LVI).Conclusion VD supplementation in patients with nonmetastatic HER2+ breast cancer is associated with improved DFS.

AB - Background Vitamin D (VD) supplementation has pleiotropic effects that extend beyond their impact on bone health, including the disruption of downstream VD receptor signaling and human epidermal growth factor receptor 2 (HER2) signaling through the ErbB2/AKT/ERK pathway. In the present study, we examined our institutional experience with patients having nonmetastatic HER2-positive (HER+) breast cancer and hypothesized that those patients who received VD supplementation during neoadjuvant chemotherapy would have improved long-term outcomes.Patients and Methods We performed a retrospective review of all patients (n = 308) given trastuzumab-based chemotherapy between 2006 and 2012 at the University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC). We identified 2 groups of patients for comparison - those who received VD supplementation during neoadjuvant chemotherapy (n = 134) and those who did not (n = 112). Univariate and multivariate Cox proportional hazard regression models were fitted to overall survival (OS) and disease-free survival (DFS).Results More than half of the patients received VD during neoadjuvant chemotherapy (54.5%), with 60% receiving a dose < 10,000 units/wk and 33.3% having a VD deficiency at the start of therapy. In our final multivariate model, VD use was associated with improved DFS (hazard ratio [HR], 0.36; 95% confidence interval [CI], 0.15-0.88; P =.026], whereas larger tumor size was associated with worse DFS (HR, 3.52; 95% CI, 1.06-11.66; P =.04). There were no differences in OS based on any of the categories, including VD use, tumor size, number of metastatic lymph nodes, age at diagnosis, or lymphovascular invasion (LVI).Conclusion VD supplementation in patients with nonmetastatic HER2+ breast cancer is associated with improved DFS.

KW - Calcitriol

KW - ErbB2/AKT/ERK pathway

KW - Pleiotropic effects

KW - Trastuzumab

KW - Vitamin D receptor

KW - Vitamin D supplementation

UR - http://www.scopus.com/inward/record.url?scp=84920271739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920271739&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2014.08.001

DO - 10.1016/j.clbc.2014.08.001

M3 - Article

C2 - 25241299

AN - SCOPUS:84920271739

VL - 15

SP - e1-e11

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 1

ER -